Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has been given an average recommendation of “Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have covered the stock in the last year is $67.60.
A number of brokerages have weighed in on ARCT. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday, July 2nd. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. Finally, Canaccord Genuity Group decreased their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a report on Friday, May 10th.
Get Our Latest Stock Analysis on ARCT
Insider Transactions at Arcturus Therapeutics
Hedge Funds Weigh In On Arcturus Therapeutics
Several institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its holdings in Arcturus Therapeutics by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,406 shares during the period. Arizona State Retirement System acquired a new position in shares of Arcturus Therapeutics in the 4th quarter valued at $211,000. Tritonpoint Wealth LLC bought a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at $885,000. DekaBank Deutsche Girozentrale increased its stake in Arcturus Therapeutics by 3.0% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 43,889 shares of the biotechnology company’s stock worth $1,401,000 after purchasing an additional 1,272 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Arcturus Therapeutics by 224.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 114,810 shares of the biotechnology company’s stock worth $3,620,000 after buying an additional 79,387 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.
Arcturus Therapeutics Price Performance
ARCT opened at $20.55 on Friday. The firm’s fifty day moving average price is $27.52 and its two-hundred day moving average price is $31.10. The company has a market capitalization of $553.41 million, a P/E ratio of -5.26 and a beta of 2.64. Arcturus Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $45.00.
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.17. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The firm had revenue of $38.01 million during the quarter, compared to analyst estimates of $22.12 million. On average, equities research analysts expect that Arcturus Therapeutics will post -4.74 EPS for the current fiscal year.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
See Also
- Five stocks we like better than Arcturus Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Basic Materials Stocks Investing
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.